Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wright Medical Augments Ortho Extremities Biz With BioMimetic Purchase

This article was originally published in The Gray Sheet

Executive Summary

Firm expects to gain PMA approval in 2013 for BioMimetic’s Augment bone graft as a replacement for autologous bone graft in foot and ankle fusion procedures. Deal includes $190 million down, and up to $190 million more in milestone payments.

You may also be interested in...



Wright Sees Potential $1B+ Market Opportunity With Newly-Approved Orthobiologic

The Augment biologic-based device was approved for use in ankle and hindfoot fusions after overcoming multiple regulatory challenges, opening up a $300 million US market opportunity. It's the first indication for a product platform that Wright hopes to extend to use in soft-tissue procedures such as rotator cuff or tennis elbow repair, which represent a $1 billion-plus opportunity.

Wright Brings New Biologic To U.S. Ortho Space With Augment Approval

The Augment biologic-based device was approved for use in ankle and hindfoot fusions after overcoming multiple regulatory challenges.

Vendor Inspections Hold Up Wright's Augment Graft Approval

Wright received an "approvable" letter from FDA about nine months ago for its Augment biologic-device bone graft, but the approval is delayed as the agency performs multiple inspections and has issued two Form-483s to a component supplier for the product.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT031771

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel